DAMORA THERAPEUTICS, INC. Retained Earnings
DAMORA THERAPEUTICS, INC. (DMRA) had Retained Earnings of -$546.32 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-10
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$546.32M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$515.15M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$487.36M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$286.63M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$546.32M 10-Q · filed 2026-08-10 |
| 2026-03-31 | -$515.15M 10-Q · filed 2026-05-12 |
| 2025-12-31 | -$487.36M 10-Q · filed 2026-08-10 |
| 2025-09-30 | -$286.63M 10-Q · filed 2025-11-06 |
| 2025-06-30 | -$283.49M 10-Q · filed 2025-08-05 |
| 2025-03-31 | -$280.06M 10-Q · filed 2025-05-08 |
| 2024-12-31 | -$277.52M 10-K · filed 2026-03-19 |
| 2024-09-30 | -$270.78M 10-Q · filed 2024-11-01 |
| 2024-06-30 | -$266.90M 8-K · filed 2024-10-07 |
| 2024-03-31 | -$261.56M 10-Q · filed 2024-04-29 |
| 2023-12-31 | -$256.08M 10-K · filed 2025-03-19 |
| 2023-09-30 | -$249.61M 10-Q · filed 2023-11-06 |
| 2023-06-30 | -$241.47M 10-Q · filed 2023-07-31 |
| 2023-03-31 | -$230.73M 10-Q · filed 2023-04-28 |
| 2022-12-31 | -$217.74M 10-K · filed 2024-03-08 |
| 2022-09-30 | -$203.67M 10-Q · filed 2022-11-08 |
| 2022-06-30 | -$189.94M 10-Q · filed 2022-07-29 |
| 2022-03-31 | -$173.05M 10-Q · filed 2022-04-29 |
| 2021-12-31 | -$156.11M 10-K · filed 2023-03-09 |
| 2021-09-30 | -$142.70M 10-Q · filed 2021-11-04 |
| 2021-06-30 | -$130.01M 10-Q · filed 2021-08-05 |
| 2021-03-31 | -$117.70M 10-Q · filed 2021-05-04 |
| 2020-12-31 | -$104.36M 10-K · filed 2022-02-17 |
| 2020-09-30 | -$92.78M 10-Q · filed 2020-12-11 |
| 2019-12-31 | -$69.52M 10-K · filed 2021-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |